Insider Purchases: Inside the Buy
Tag: Insider Purchases
🏥 Elevance Health (NYSE: ELV): The CEO Bought Again. We're Still Buying the Story.
Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🚀 Insperity (NSP): Why the CEO Just Bought Another $7.9M of This HR Stock
Insperity (NYSE: NSP) continues attracting major insider buying. CEO Paul Sarvadi has now purchased roughly $15.5 million of stock in less than three months, including a new $7.9 million purchase after shares rallied nearly 50%.
📈 Top Insider Buys April 2026: PRLD, THM, TORO, SMPL & More
Insiders are buying across biotech, mining, shipping, AI, banking, snacks, water infrastructure, and cybersecurity. Here’s what the biggest Week 3 April 2026 buys may signal.
SSP Stock Analysis 2026: Scripps Insiders Double Down on a High-Stakes Media Turnaround
When insiders start buying stock aggressively, investors take notice. In early 2026, executives, directors, and members of the Scripps family all stepped in to buy SSP shares. The question now: is this a deep-value media turnaround or a value trap?
KKR: The Private Equity Giant Offering Public-Scale Prosperity
KKR is no longer just for billionaires in wood-paneled boardrooms. With insiders buying, earnings compounding, and shares still ~38% below highs, the private equity giant looks like public-scale opportunity.
Ryan Cohen Buys More GameStop; Time to Play — or Make This Story Short?
Ryan Cohen doubles down on GameStop. Shorts stay crowded. Analysts stay bearish. But profits, cash, and conviction are back. Is GME still a meme — or a mispriced turnaround? 🎯🎮
Director Purchases Shares of Johnson & Johnson
A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?
Is Magnera Engineering Not Only Materials… but Also a Turnaround?
Magnera Corporation is showing signs of a real turnaround — insiders are buying, institutions are crowding in, cash flow is surging, and valuations remain bargain-level. A quirky, fun deep dive into one of the market’s most overlooked industrial players.
Sweetgreen Update: When the CEO Buys the Salad Dip
Sweetgreen (SG) just delivered a wild mix of insider buying, lowered guidance, widening losses, and surprising institutional support. With the CEO buying $1M+ of stock at the lows and valuation at historic discounts, the setup is intriguing — but still risky. Here’s the full FUNanc1al breakdown.